IQV (Iqvia Holdings Inc.) — AI Stock Analysis & Recommendation

Research of October 2, 2026 · Healthcare / Services-Commercial Physical & Biological Research

TradeFlare's AI research teams rate IQV a BUY. The latest price is $260.68.

The research plan

• Entry: $258.21
• Target: $284.03
• Stop: $232.39
• Time horizon: days

The scanner trigger is a short-term mean-reversion signal, and the technicals are neutral, suggesting a quick bounce is expected.

Why

The scanner trigger is a short-term mean-reversion signal, and the technicals are neutral, suggesting a quick bounce is expected. Catalysts to watch: Strong Q2 2026 earnings beat and raised guidance; Robust backlog and positive analyst sentiment driven by accelerating growth; Attractive valuation with a forward P/E of 17.84 and PEG ratio of 0.95. Key risks: High debt-to-equity ratio (257.98%) and elevated volatility; Technicals show bearish momentum signals (MACD, Stochastic) despite an uptrend; Increasing global data privacy regulations could pose a challenge.

What could push IQV higher

• Strong Q2 2026 earnings beat and raised guidance.
• Robust backlog and positive analyst sentiment driven by accelerating growth.
• Attractive valuation with a forward P/E of 17.84 and PEG ratio of 0.95.

Key risks for IQV

• High debt-to-equity ratio (257.98%) and elevated volatility.
• Technicals show bearish momentum signals (MACD, Stochastic) despite an uptrend.
• Increasing global data privacy regulations could pose a challenge.

What each AI research team found

Fundamental team: Bullish · valuation: undervalued

IQVIA presents a compelling investment case with its dominant market position, integrated business model, and strong competitive moat. Despite high leverage, robust free cash flow, positive growth trends, and attractive valuation metrics supported by analyst consensus suggest undervaluation. The stock is poised for upside towards its mean analyst target price, contingent on continued operational execution and...

• IQVIA's integrated business model (CRO + Data/Analytics) creates a powerful synergy and a strong competitive moat, supported by extensive proprietary data assets and advanced analytics capabilities.
• Despite a high debt-to-equity ratio (257.98%), the company demonstrates strong free cash flow generation (TTM $2.18B) and adequate interest coverage (3.06x), with management raising full-year guidance.
• The forward P/E of 17.84 and PEG ratio of 0.95 suggest the stock is attractively valued relative to its expected earnings growth, further supported by a 'strong_buy' analyst consensus with a mean target price of $288.74.

Technical team: Neutral

The technical analysis presents a mixed picture with an uptrend approaching resistance, but bearish momentum signals and subdued volume suggest caution. The stock is currently in a neutral consolidation phase near a key resistance level, making a decisive verdict difficult without a clear breakout or breakdown.

• The price is in an uptrend and approaching resistance; a breakout above $258.72 could signal further upside, while a rejection might lead to a pullback.
• The stock is trading near resistance with mixed volume signals, suggesting a neutral short-term outlook as it consolidates within a defined range.
• The price is consolidating near resistance with bearish signals from MACD and Stochastic, suggesting a potential pullback towards support levels.

Sentiment team: Bullish

IQVIA exhibits strong positive sentiment across news, social, and analyst channels, driven by robust financial performance and strategic initiatives. While some concerns exist regarding regulatory pressures and insider selling, the overwhelming positive catalysts and analyst consensus suggest an improving outlook and potential for further upside.

• IQVIA is experiencing positive news sentiment driven by a strong Q2 2026 earnings beat, raised guidance, robust backlog, and strategic AI adoption, despite concerns regarding data privacy and pricing pressures. (Score: 0.2)
• Retail investor sentiment for IQVIA is cautiously optimistic, driven by its strong industry position, positive analyst outlook, and growth potential in the evolving biotech landscape. (Score: 0.15)
• IQVIA exhibits predominantly positive analyst sentiment driven by strong earnings, accelerating growth, and a robust pipeline, despite some recent downgrades and insider selling concerns. (Consensus: Strong Buy)

Risk team: High

IQV presents a high-risk profile due to significant historical drawdowns, elevated volatility, and substantial leverage. The company's high debt-to-equity ratio and low current ratio, coupled with moderate interest coverage, amplify financial risks, especially in a rising rate environment. Given these factors, a small position size with a tight stop-loss is recommended.

• Deep Drawdown (1Y): The stock has experienced a significant drawdown of -47.12% over the past year, indicating substantial price volatility and potential for sharp declines.
• High Leverage: IQVIA has a very high debt-to-equity ratio (257.98%), suggesting a significant reliance on debt financing, which increases financial risk, especially in a rising interest rate environment.
• Elevated Volatility: Annualized volatility metrics (20d: 24.1%, 60d: 39.6%) are high, especially the 60-day figure, suggesting significant price fluctuations.

IQV at a glance

Market value	$43.4B
Price / earnings	32.0
Revenue growth (year over year)	7.3%
Profit margin	8.3%
Debt / equity	2.25

Every AI call on IQV since July 31, 2026, and what happened next (4 calls) →

Research of October 2, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.